Alcobra Ltd.(ADHD)- NASDAQ
  • Mon, Sep. 12, 11:00 AM
    | Mon, Sep. 12, 11:00 AM
  • Tue, Aug. 30, 12:47 PM
    | Tue, Aug. 30, 12:47 PM
  • Tue, Aug. 30, 11:01 AM
    | Tue, Aug. 30, 11:01 AM | 1 Comment
  • Tue, Aug. 30, 7:53 AM
    • Alcobra (ADHD) Q2 results: Revenues: $0; R&D Expense: $4.2M (+13.5%); SG&A: $1.4M (+16.7%); Net Loss: ($5.8M) (-13.7%); Loss Per Share: ($0.21) (+12.5%); Quick Assets: $53.1M (+4.7%); CF Ops: ($4.1M) (-5.1%).
    • No guidance given.
    • Shares are down 14% on a 5x surge in volume.
    | Tue, Aug. 30, 7:53 AM
  • Tue, Aug. 30, 7:04 AM
    • Alcobra (NASDAQ:ADHD): Q2 EPS of -$0.21 beats by $0.01.
    • Cash and cash equivalents of $15.1M
    • Press Release
    | Tue, Aug. 30, 7:04 AM
  • Mon, May 16, 9:30 AM
    • Alcobra (ADHD) Q1 results: Revenues: $0; R&D Expense: $3.4M (-5.6%); SG&A: $1.5M (+15.4%); Net Loss: ($5.1M) (+1.9%); Loss Per Share: ($0.18) (+30.8%); Quick Assets: $53.2M (+4.9%); CF Ops: ($4.4M) (+4.3%).
    • No guidance given.
    | Mon, May 16, 9:30 AM
  • Mon, May 16, 8:04 AM
    • Alcobra (NASDAQ:ADHD): Q1 EPS of -$0.18 beats by $0.04.
    • Cash and cash equivalents of $13.5M
    • Press Release
    | Mon, May 16, 8:04 AM
  • Fri, Feb. 19, 8:22 AM
    • MacroGenics (NASDAQ:MGNX) initiated with Buy rating and $36 (110% upside) price target by Janney Capital.
    • Alcobra (NASDAQ:ADHD) initiated with Buy rating with a $10 (95% upside) price target by Jefferies.
    • Valeant Pharmaceuticals (NYSE:VRX) initiated with Buy rating and $150 (60% upside) price target by Rodman & Renshaw.
    • Ocular Therapeutix (NASDAQ:OCUL) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target maintained at $15 (81% upside).
    • HealthStream (NASDAQ:HSTM) upgraded to Buy from Hold with a price target of $25 (16% upside) by Needham.
    • Juno Therapeutics (NASDAQ:JUNO) upgraded to Buy from Neutral by Guggenheim.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) upgraded to Neutral from Sell by Chardan Capital. Price target lowered to $375 (3% downside risk) from $400.
    • Community Health Systems (NYSE:CYH) downgraded to Market Perform from Outperform by Avondale. Price target lowered to $18 (20% upside).
    | Fri, Feb. 19, 8:22 AM | 7 Comments
  • Wed, Feb. 17, 10:03 AM
    • Alcobra (ADHD +2.2%) Q4 results: Revenues: $0; R&D Expense: $3.3M (-32.7%); SG&A: $1.3M (-7.1%); Net Loss: ($4.9M) (+27.9%); Loss Per Share: ($0.20) (+60.0%).
    • FY2015 results: Revenues: $0; R&D Expense: $13.5M (-46.2%); SG&A: $5M (-13.8%); Net Loss: ($19.4M) (+40.9%); Loss Per Share: ($0.90) (+62.5%); Quick Assets: $40.7M (+87.6%).
    • No guidance given.
    | Wed, Feb. 17, 10:03 AM
  • Wed, Feb. 17, 8:02 AM
    • Alcobra (NASDAQ:ADHD): Q4 EPS of -$0.20 beats by $0.04.
    | Wed, Feb. 17, 8:02 AM
  • Wed, Feb. 10, 10:40 AM
    • The FDA designates Amarantus BioScience Holdings' (OTCQX:AMBS +11.1%) eltoprazine an Orphan Drug for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).
    • Phase 2-stage eltoprazine, a small molecule neuromodulator, is a 5HT 1A/1B receptor agonist under development for PD-LID and adult attention deficit hyperactivity disorder (NASDAQ:ADHD).
    • PD-LID is an involuntary movement disorder that results from prolonged levodopa-based therapy, the standard-of-care for patients with Parkinson's disease. PD-LID occurs in as many as 80% of PD patients. It is difficult to treat and prevents patients from performing routine daily tasks.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
    • Previously: First patient dosed in Amarantus Bio's mid-stage study of eltoprazine in movement disorder (July 20, 2015)
    | Wed, Feb. 10, 10:40 AM
  • Nov. 13, 2015, 5:44 PM
    • Top gainers, as of 5.25 p.m.: SIGM +9.8%. TVIX +2.1%. ITUB +2.0%. AVL +1.9%.
    • Top losers, as of 5.25p.m.: ECA -6.7%. FCAU -5.0%. ADHD -3.2%. OCAT -1.9%.
    | Nov. 13, 2015, 5:44 PM | 10 Comments
  • Nov. 13, 2015, 10:54 AM
    • Alcobra (ADHD -14.3%) prices its previously announced public offering of 6.175M shares of common stock at $6.50 per share. Underwriters over-allotment is an additional 926,250 shares. Closing date is November 18.
    | Nov. 13, 2015, 10:54 AM
  • Nov. 12, 2015, 4:50 PM
    • Alcobra (NASDAQ:ADHD): Q3 EPS of -$0.20 beats by $0.11.
    | Nov. 12, 2015, 4:50 PM
  • Sep. 21, 2015, 9:19 AM
    | Sep. 21, 2015, 9:19 AM | 9 Comments
  • Sep. 21, 2015, 9:03 AM
    • The FDA designates Alcobra's (NASDAQ:ADHD) MDX for Fast Track review for the treatment of Fragile X syndrome, an inherited caused by mutations in the FMR1 gene that results in a range of developmental problems such as learning disabilities and cognitive impairment. It affects one in 4,000 males and one in 6,000 females.
    • Orphan Drug-tagged Metadoxine Extended Release (MDX) is a modulator of GABA (gamma-aminobutyric acid), an abundant neurotransmitter in the central nervous system, especially in the cerebral cortex where thinking occurs and sensations are interpreted. It is in Phase 2 development for Fragile X and Phase 3 development for the treatment of adults with attention deficit hyperactivity disorder (ADHD).
    • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
    • Shares are up 14% premarket on increased volume.
    | Sep. 21, 2015, 9:03 AM | 2 Comments